Literature DB >> 26301605

MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis.

Liu Tao1, Zuo Li2, Li Lin3, Yin Lei1, Yu Hongyuan1, Jing Hongwei1, Liu Yang1, Kong Chuize1.   

Abstract

BACKGROUND: The matrix metalloproteinases (MMPs) are a family of highly conserved, metal-dependent proteolytic enzymes that play an important role in tumor invasion and metastasis. Many studies have been carried out on the association between polymorphisms in the MMP1, MMP2, MMP3, MMP7, and MMP9 genes and urinary cancer risk. However, the data from these published studies are conflicting and have low statistical power.
METHODS: In this study, we performed a meta-analysis of 12 different publications from the PubMed and WanFang databases, published up to May 2015, to better assess the purported associations. Odds ratios (OR) and 95% confidence intervals (CI) were determined to reveal association strengths.
RESULTS: Some significant associations were found. For the MMP1 -1607 1G/2G polymorphism, a negative association was identified for the 2G allele in bladder cancer (2G2G+2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.36-0.93, pheterogeneity = 0.001) and renal cell carcinoma (2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.39-0.82, pheterogeneity = 0.567). For the MMP2 -1306 C/T polymorphism, there was a negative association with the T allele for bladder cancer in the Asian population (TT+TC vs. CC: OR = 0.41, 95% CI = 0.18-0.94, pheterogeneity = 0.195). For the MMP7 -181 A/G polymorphism, a decreased bladder cancer risk was found (G-allele vs. A-allele: OR = 0.81, 95% CI = 0.66-0.98, pheterogeneity =0.325).
CONCLUSION: In summary, our study showed evidence that genetic polymorphisms in MMP1 for all populations, but only in the Asian population for MMP2 and MMP7, may protect against bladder cancer risk. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26301605      PMCID: PMC4599389          DOI: 10.1089/gtmb.2015.0123

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  43 in total

1.  Matrix metalloproteinase polymorphisms and bladder cancer risk.

Authors:  A Karim Kader; Lina Shao; Colin P Dinney; Matthew B Schabath; Yunfei Wang; Jun Liu; Jian Gu; H Barton Grossman; Xifeng Wu
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

2.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis.

Authors:  B Zhang; S Ye; S M Herrmann; P Eriksson; M de Maat; A Evans; D Arveiler; G Luc; F Cambien; A Hamsten; H Watkins; A M Henney
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

3.  Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer.

Authors:  Kürşat Oğuz Yaykaşli; Muhammet Ali Kayikçi; Nesibe Yamak; Hatice Soğuktaş; Selma Düzenli; Ali Osman Arslan; Ahmet Metın; Ertuğrul Kaya; Ömer Faruk Hatıpoğlu
Journal:  Turk J Med Sci       Date:  2014       Impact factor: 0.973

4.  Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation.

Authors:  S J Price; D R Greaves; H Watkins
Journal:  J Biol Chem       Date:  2000-12-12       Impact factor: 5.157

5.  Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma.

Authors:  Hiroshi Hirata; Naoko Okayama; Katsusuke Naito; Ryo Inoue; Satoru Yoshihiro; Hideyasu Matsuyama; Yutaka Suehiro; Yuichiro Hamanaka; Yuji Hinoda
Journal:  Carcinogenesis       Date:  2004-08-19       Impact factor: 4.944

6.  Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer.

Authors:  Norihiko Tsuchiya; Shintaro Narita; Teruaki Kumazawa; Takamitsu Inoue; Zhiyong Ma; Hiroshi Tsuruta; Mitsuru Saito; Yohei Horikawa; Takeshi Yuasa; Shigeru Satoh; Osamu Ogawa; Tomonori Habuchi
Journal:  Oncol Rep       Date:  2009-09       Impact factor: 3.906

7.  Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility.

Authors:  Edyta Wieczorek; Edyta Reszka; Zbigniew Jablonowski; Ewa Jablonska; Magdalena Beata Krol; Adam Grzegorczyk; Jolanta Gromadzinska; Marek Sosnowski; Wojciech Wasowicz
Journal:  BJU Int       Date:  2013-07-02       Impact factor: 5.588

8.  Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences.

Authors:  R Gum; E Lengyel; J Juarez; J H Chen; H Sato; M Seiki; D Boyd
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

9.  MMP7 and MMP8 genetic polymorphisms in bladder cancer patients.

Authors:  Edyta Wieczorek; Edyta Reszka; Wojciech Wasowicz; Adam Grzegorczyk; Tomasz Konecki; Marek Sosnowski; Zbigniew Jablonowski
Journal:  Cent European J Urol       Date:  2014-01-27

10.  Systematic evaluation and comparison of statistical tests for publication bias.

Authors:  Yasuaki Hayashino; Yoshinori Noguchi; Tsuguya Fukui
Journal:  J Epidemiol       Date:  2005-11       Impact factor: 3.211

View more
  10 in total

1.  The association between matrix metalloproteinase-7 genetic variant and bladder cancer risk in a Chinese Han population.

Authors:  Fei Mao; Xiao-Bing Niu; Shuo Gu; Lu Ji; Bing-Jian Wei; Heng-Bing Wang
Journal:  Clin Exp Med       Date:  2019-10-01       Impact factor: 3.984

Review 2.  Zebrafish Xenograft: An Evolutionary Experiment in Tumour Biology.

Authors:  Rachael A Wyatt; Nhu P V Trieu; Bryan D Crawford
Journal:  Genes (Basel)       Date:  2017-09-05       Impact factor: 4.096

3.  The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis.

Authors:  Kun Liu; Shuo Gu; Xuzhong Liu; Qing Sun; Yunyan Wang; Junsong Meng; Zongyuan Xu
Journal:  Oncotarget       Date:  2017-05-19

Review 4.  Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects.

Authors:  Kaiping Zhang; Xianguo Chen; Jun Zhou; Cheng Yang; Meng Zhang; Min Chao; Li Zhang; Chaozhao Liang
Journal:  Oncotarget       Date:  2017-07-04

5.  MicroRNA-146b Overexpression Promotes Human Bladder Cancer Invasion via Enhancing ETS2-Mediated mmp2 mRNA Transcription.

Authors:  Junlan Zhu; Chunxia Xu; Liming Ruan; Jianping Wu; Yang Li; Xingguo Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2019-04-14       Impact factor: 8.886

6.  Key genes affecting the progression of nasopharyngeal carcinoma identified by RNA-sequencing and bioinformatic analysis.

Authors:  Yihong Wang; Manyi Li; Yan Guo; Haiping Huang; Xuelin Dong; Yangguang Sun; Jisheng Liu
Journal:  Aging (Albany NY)       Date:  2021-09-20       Impact factor: 5.682

7.  Melanoma differentiation-associated gene-7 suppresses human gastric cancer cell invasion and migration.

Authors:  Li Xu; Jinyan Chen; Wei Lin; Jinkun Chen; Zhiwei Chen
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

8.  Matrix Metalloproteinases Polymorphisms as Baseline Risk Predictors in Malignant Pleural Mesothelioma.

Authors:  Danijela Strbac; Katja Goricar; Vita Dolzan; Viljem Kovac
Journal:  Radiol Oncol       Date:  2018-02-07       Impact factor: 4.214

9.  lncRNA SNHG1 Promotes Basal Bladder Cancer Invasion via Interaction with PP2A Catalytic Subunit and Induction of Autophagy.

Authors:  Jiheng Xu; Rui Yang; Xiaohui Hua; Maowen Huang; Zhongxian Tian; Jingxia Li; Hoi Yun Lam; Guosong Jiang; Mitchell Cohen; Chuanshu Huang
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-18       Impact factor: 8.886

10.  PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.

Authors:  Minggang Peng; Jingjing Wang; Dongyun Zhang; Honglei Jin; Jingxia Li; Xue-Ru Wu; Chuanshu Huang
Journal:  Oncogene       Date:  2018-06-21       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.